NCT00011037View on ClinicalTrials.gov

ALVAC-HIV vCP1452 Alone and Combined With MN rgp120

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 2004

Conditions
HIV InfectionsHIV Seronegativity
Interventions
BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452)

1 x 10\^ 7 TCID50 administered intramuscularly

BIOLOGICAL

MN rgp120/HIV-1

0.6 mg administered intramuscularly

BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452) placebo

ALVAC placebo administered intramuscularly

BIOLOGICAL

MN rgp120/HIV-1 placebo

Alum placebo administered intramuscularly

Trial Locations (4)

Unknown

Projeto Praça Onze/Hesfa Crs, Rio de Janeiro

Les Centres GHESKIO CRS, Port-au-Prince

Barranco CRS, Lima

CCPRI Med. Ctr. - Med. Research Foundation of Trinidad & Tobago, Port of Spain

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH